vs
Side-by-side financial comparison of Viridian Therapeutics, Inc.\DE (VRDN) and Waldencast plc (WALD). Click either name above to swap in a different company.
Waldencast plc is the larger business by last-quarter revenue ($108.8M vs $70.6M, roughly 1.5× Viridian Therapeutics, Inc.\DE). Viridian Therapeutics, Inc.\DE runs the higher net margin — -49.0% vs -55.7%, a 6.6% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 17.8%). Waldencast plc produced more free cash flow last quarter ($-13.9M vs $-84.7M).
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
Waldencast plc is a global multi-brand platform focused on acquiring, developing and scaling high-growth premium niche brands across the beauty, personal care and wellness sectors. It operates primarily across North America and European markets, with core offerings including clean skincare, haircare, color cosmetics and wellness products targeted at quality-focused consumers.
VRDN vs WALD — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2023
| Metric | | |
|---|---|---|
| Revenue | $70.6M | $108.8M |
| Net Profit | $-34.6M | $-60.6M |
| Gross Margin | — | 67.5% |
| Operating Margin | -56.7% | -42.9% |
| Net Margin | -49.0% | -55.7% |
| Revenue YoY | 81958.1% | 17.8% |
| Net Profit YoY | 54.9% | — |
| EPS (diluted) | — | $-0.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $70.6M | — | ||
| Q4 23 | — | $108.8M | ||
| Q2 23 | — | $109.3M | ||
| Q4 22 | — | $92.4M |
| Q3 25 | $-34.6M | — | ||
| Q4 23 | — | $-60.6M | ||
| Q2 23 | — | — | ||
| Q4 22 | — | — |
| Q3 25 | — | — | ||
| Q4 23 | — | 67.5% | ||
| Q2 23 | — | 62.4% | ||
| Q4 22 | — | 34.3% |
| Q3 25 | -56.7% | — | ||
| Q4 23 | — | -42.9% | ||
| Q2 23 | — | -37.8% | ||
| Q4 22 | — | -136.8% |
| Q3 25 | -49.0% | — | ||
| Q4 23 | — | -55.7% | ||
| Q2 23 | — | — | ||
| Q4 22 | — | — |
| Q3 25 | — | — | ||
| Q4 23 | — | $-0.65 | ||
| Q2 23 | — | — | ||
| Q4 22 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $490.9M | $21.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $503.0M | $624.6M |
| Total Assets | $577.1M | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $490.9M | — | ||
| Q4 23 | — | $21.1M | ||
| Q2 23 | — | — | ||
| Q4 22 | — | $8.7M |
| Q3 25 | — | — | ||
| Q4 23 | — | — | ||
| Q2 23 | — | — | ||
| Q4 22 | — | $179.3M |
| Q3 25 | $503.0M | — | ||
| Q4 23 | — | $624.6M | ||
| Q2 23 | — | $767.3M | ||
| Q4 22 | — | $639.2M |
| Q3 25 | $577.1M | — | ||
| Q4 23 | — | $1.0B | ||
| Q2 23 | — | — | ||
| Q4 22 | — | $1.1B |
| Q3 25 | — | — | ||
| Q4 23 | — | — | ||
| Q2 23 | — | — | ||
| Q4 22 | — | 0.28× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-84.6M | $-13.4M |
| Free Cash FlowOCF − Capex | $-84.7M | $-13.9M |
| FCF MarginFCF / Revenue | -120.1% | -12.7% |
| Capex IntensityCapex / Revenue | 0.2% | 0.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-84.6M | — | ||
| Q4 23 | — | $-13.4M | ||
| Q2 23 | — | — | ||
| Q4 22 | — | — |
| Q3 25 | $-84.7M | — | ||
| Q4 23 | — | $-13.9M | ||
| Q2 23 | — | — | ||
| Q4 22 | — | — |
| Q3 25 | -120.1% | — | ||
| Q4 23 | — | -12.7% | ||
| Q2 23 | — | — | ||
| Q4 22 | — | — |
| Q3 25 | 0.2% | — | ||
| Q4 23 | — | 0.4% | ||
| Q2 23 | — | 1.0% | ||
| Q4 22 | — | 1.5% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
